About
Technology
Issues
FAQ
Links
Official Page
A Randomized Phase 2 Study of Erlotinib Plus Pemetrexed vs Erlotinib or Pemetrexed Alone as Second-Line Treatment for Never-Smoker Patients with Non-Squamous Advanced Non-Small Cell Lung Cancer (NSCLC)
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.